Lumeng J. Yu

ORCID: 0000-0003-0370-4444
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neonatal Respiratory Health Research
  • Diet and metabolism studies
  • Clinical Nutrition and Gastroenterology
  • Metabolism and Genetic Disorders
  • Congenital Diaphragmatic Hernia Studies
  • Pulmonary Hypertension Research and Treatments
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Neuroscience and Neuropharmacology Research
  • Cancer, Stress, Anesthesia, and Immune Response
  • Respiratory Support and Mechanisms
  • Diet, Metabolism, and Disease
  • RNA Interference and Gene Delivery
  • Reproductive System and Pregnancy
  • Cancer, Hypoxia, and Metabolism
  • Melanoma and MAPK Pathways
  • Inhalation and Respiratory Drug Delivery
  • Chemical Synthesis and Analysis
  • Liver Disease Diagnosis and Treatment
  • 3D Printing in Biomedical Research
  • Cytokine Signaling Pathways and Interactions
  • Cholesterol and Lipid Metabolism
  • Beetle Biology and Toxicology Studies
  • Genomics and Chromatin Dynamics
  • Surgical Sutures and Adhesives
  • Advanced biosensing and bioanalysis techniques

Boston Children's Hospital
2019-2023

Harvard University
2020-2023

Beth Israel Deaconess Medical Center
2022

Boston Children's Museum
2019-2021

Center for Vascular Biology Research
2020

Rutgers, The State University of New Jersey
2013-2018

Johnson University
2015

University at Buffalo, State University of New York
1982

Scientific Research Institute of Biochemistry
1976

Abstract Acute respiratory distress syndrome is the most severe form of acute lung injury (ALI) and associated with significant mortality. Lipopolysaccharide (LPS)-induced a valuable murine model ALI but there paucity data on regeneration role angiogenic signaling involving vascular endothelial growth factor (VEGF). Eight-week-old male C57BL/6J mice were randomized to receive intratracheal instillation either LPS or isovolumetric phosphate buffered saline as vehicle control. Mice observed at...

10.1038/s41598-022-14618-8 article EN cc-by Scientific Reports 2022-06-17

Summary Gain of function the neuronal receptor, metabotropic glutamate receptor 1 ( G rm1), was sufficient to induce melanocytic transformation in vitro and spontaneous melanoma development vivo when ectopically expressed melanocytes. The human form this GRM 1, has been shown be a subset melanomas but not benign nevi or normal melanocytes, suggesting that misregulation is involved pathogenesis certain melanomas. Sustained stimulation rm1 by ligand, glutamate, required for maintenance...

10.1111/pcmr.12207 article EN Pigment Cell & Melanoma Research 2013-12-11

Emphysema is a progressive and fatal lung disease with no cure that characterized by thinning, enlargement, destruction of alveoli, leading to impaired gas exchange. Disease progression due in part dysregulation VEGF (vascular endothelial growth factor) signaling the lungs increased lung-cell apoptosis. Here we asked whether PR1P (Prominin-1–derived peptide), novel short peptide designed increases binding cells, could be used improve outcome vitro vivo models emphysema. We computer...

10.1165/rcmb.2019-0434oc article EN American Journal of Respiratory Cell and Molecular Biology 2020-07-14

Approximately 50% of patients having metastatic melanoma develop brain metastases during the course their illness. Evidence exists that cells have increased aptitude for repair sublethal DNA damage caused by ionizing radiation therapy. To address radio-resistance melanoma, many groups adopted radiotherapy schedules deliver larger daily fractions radiation, but due to risk neurotoxicity, these large cannot be delivered whole with metastases. Here, we used orthotopic implanted GRM1 expressing...

10.1111/pcmr.12327 article EN Pigment Cell & Melanoma Research 2014-11-01

Intestinal failure-associated liver disease (IFALD), initially manifesting as cholestasis, is a complication in neonates receiving parenteral nutrition (PN). Soybean oil lipid emulsion (SOLE), though implicated IFALD, was the only US Food and Drug Administration (FDA)-approved initial intravenous (ILE) for infants children United States. A mixed-oil (MOLE) gained popularity patients at risk IFALD recently FDA approved an ILE children. Given presence of soybean MOLE, we hypothesized that MOLE...

10.1002/jpen.2458 article EN Journal of Parenteral and Enteral Nutrition 2022-10-29

Abstract Morbidity and mortality for neonates with congenital diaphragmatic hernia-associated pulmonary hypoplasia remains high. These patients may be deficient in vascular endothelial growth factor (VEGF). Our lab previously established that exogenous VEGF164 accelerates compensatory lung (CLG) after left pneumonectomy a murine model. We aimed to further investigate VEGF-mediated CLG by examining the role of heparin-binding domain (HBD). Eight-week-old, male, C57BL/6J mice underwent...

10.1038/s41598-021-91127-0 article EN cc-by Scientific Reports 2021-06-04

The non-canonical NF-κB signaling (RelB/p52) pathway drives pro-labor genes in the human placenta, including corticotropin-releasing hormone (CRH) and cyclooxygenase-2 (COX-2), making this a potential therapeutic target to delay onset of labor. Here we sought identify small molecule compounds from pre-existing chemical library orally active drugs that can inhibit signaling, turn, placental CRH COX-2 production. We used cell-based assay coupled with dual-luciferase reporter system perform an...

10.1038/s41598-018-20147-0 article EN cc-by Scientific Reports 2018-01-22

U1 Adaptor is a recently discovered oligonucleotide-based gene-silencing technology with unique mechanism of action that targets nuclear pre-mRNA processing. Adaptors have two distinct functional domains, both which must be present on the same oligonucleotide to exert their function. Here, we first in vivo use by targeting different human genes implicated melanomagenesis, B-cell lymphoma 2 (BCL2) and metabotropic glutamate receptor 1 (GRM1), melanoma cell xenograft mouse model system. Using...

10.1038/mtna.2013.24 article EN cc-by-nc-nd Molecular Therapy — Nucleic Acids 2013-01-01

Short bowel syndrome (SBS) occurs after intestinal loss resulting in parenteral nutrition dependence and micronutrient deficiencies, which may lead to life-limiting complications. ALC-078 is a cartridge containing immobilized lipase that connects in-line with enteral feeding sets digests fats (EN). In this study, we evaluate the efficacy of improve fat nutrient absorption porcine SBS model.Fifteen male Yorkshire piglets were assessed. Animals randomized no resection (n = 5), 75% or + 5)....

10.1016/j.clnu.2022.03.026 article EN cc-by Clinical Nutrition 2022-03-31

Background Parenteral (intravenous) nutrition is lifesaving for patients with intestinal failure, but long-term use of parenteral often leads to liver disease. SEFA-6179 a synthetic medium-chain fatty acid analogue designed target multiple receptors regulating metabolic and inflammatory pathways. We hypothesized that would prevent hepatosteatosis lipotoxicity in murine model nutrition-induced hepatosteatosis. Methods Two vivo experiments were conducted. In the first experiment, six-week-old...

10.1371/journal.pone.0295244 article EN cc-by PLoS ONE 2023-12-01

// Ho-Chung Chen 1, * , Jairo Sierra 2, Lumeng Jenny Yu Robert Cerchio Jr. 3 Brian A. Wall 4 James Goydos 5 and Suzie 3, 1 Susan Lehman Cullman Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers, The State University New Jersey, Piscataway 08854, NJ, USA 2 Rutgers-GSBS at Wood Johnson Medical School, Pharmacology Toxicology Graduate Program, Rutgers University, Global Product Safety, Colgate-Palmolive Company, Institute Brunswick 08903, These authors contributed equally...

10.18632/oncotarget.23637 article EN Oncotarget 2017-12-23

Abstract Obesity is a global epidemic that drives morbidity and mortality through cardiovascular disease, diabetes, non‐alcoholic fatty liver disease (NAFLD). No definitive therapy has been approved to improve glycemic control treat NAFLD in obese patients. Here, we investigated semi‐synthetic, long chain, structurally‐engineered acid‐1024 (SEFA‐1024), as treatment for obesity‐induced hyperglycemia, insulin‐resistance, rodent models. A single dose of SEFA‐1024 was administered evaluate...

10.1002/lipd.12351 article EN Lipids 2022-07-01
Coming Soon ...